Adenocarcinoma of the pancreas is a cancer with a poor prognosis; most patients are initially diagnosed in an advanced stage and less than 5% of patients are alive at 5 years. We carried out a retrospective study on patients treated for pancreatic cancer in the Medical Oncology department - CHU Tlemcen between the period 2010-2020; we analyzed the epidemiological, clinical, histological and therapeutic characteristics. One hundred thirty patients were identified; 56% were male; median age at diagnosis was 61.2 years [41-111]. Fifty patients were treated for diabetes (18 DNID, 32 DID). Forty-one patients were smokers (average duration of smoking was 26 years), twenty-seven patients had a family history of cancer in the 1st degree (colon, breast). Abdominal pain syndrome was the main reason for consultation, 76 patients lost weight, the average weight lost was 13 kg, 31 patients had icterus. The median time to diagnosis was 4 months [1-8], The most common primary tumor site was located in the head of the pancreas (70 cases) followed by the body (31 cases) and rarely in the tail (24 cases). The disease was diagnosed as localized in 5% of the cases, locally advanced in 32% of the cases, and at a metastatic stage in 63% of the cases. The most common metastatic site was liver (59 cases), peritoneum and ascites (28 cases). Adenocarcinoma was the first histological type. ECOG performance index was good (OMS 0 – I) in 53 patients, intermediate (OMS II) in 37 patients and altered (OMS III- IV) in 15 patients. Only 6 patients were candidates for radical surgery, a type cephalic duodeno-pancreatectomy and distal pancreatectomy with or without splenectomy in 2 patients followed by adjuvant chemotherapy with gemcitabine with an average of 6 courses. For locally advanced and/or metastatic pancreatic cancers, palliative surgery before starting chemotherapy was achieved in 24 patients, such as internal (20 cases) and external biliary drainage (4 cases). First-line palliative chemotherapy has been proposed in 66 patients, based on monotherapy such as gemcitabine (45 patients) or capecitabine (3 patients) and polychemotherapy such as Fofirinox (2 patients), Gemox (11 patients), and Gemcis (3 patients). Average number of courses was 3 [1 - 11]. The second-line chemotherapy was prescribed in 19 patients based on polychemotherapy (Folfox or Xelox,) and monotherapy based on capecitabine or gemcitabine. The average number of courses was 4. Only 3 patients accessed the third line (irinotecan or capecitabine). The median survival time was 4 months [1-7]. Pancreatic cancer has one of the lowest survivability ratings of all human cancers. Hopes are based on the development of more active molecules and of means contributing to early diagnosis or even screening.